Agenus (AGEN) Interest Expenses (2010 - 2026)
Agenus (AGEN) posted quarterly Interest Expenses of $14.7 million for Q1 2026, up 13.15% year-over-year from $13.0 million in Q1 2025, and down 8.47% quarter-over-quarter from $16.0 million in Q4 2025.
Agenus (AGEN) Interest Expenses (2010 - 2026) Analysis & Trends
Agenus' Interest Expenses history runs 17 years deep, the most recent figure standing at $14.7 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 13.15% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $57.1 million (down 44.67% YoY), while the FY2025 annual figure was $395.3 million, down 1.55% from the prior year.
- Interest Expenses for Q1 2026 stood at $14.7 million, down from $16.0 million in the prior quarter.
- The five-year high for Interest Expenses was $101.3 million in Q4 2023, with the low at $296000.0 in Q4 2022.
- The 5-year median for Interest Expenses is $13.0 million (2025), against an average of $16.8 million.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses slumped 99.06% in 2022, then soared 34132.09% in 2023.
- Agenus' Interest Expenses stood at $296000.0 in 2022, then jumped by 34132.09% to $101.3 million in 2023, then tumbled by 79.16% to $21.1 million in 2024, then fell by 23.99% to $16.0 million in 2025, then fell by 8.47% to $14.7 million in 2026.
- Business Quant data shows AGEN's Interest Expenses at $14.7 million in Q1 2026, $16.0 million in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Agenus | 311.95 Mn | 286.43 Mn | 34.52 Mn | 15.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.36 Mn |
| Jun 30, 2026 | 15.36 Mn |
| Mar 31, 2026 | 14.69 Mn |
| Mar 31, 2026 | 14.69 Mn |
| Dec 31, 2025 | 16.05 Mn |
| Dec 31, 2025 | 16.05 Mn |
| Sep 30, 2025 | 2.43 Mn |
| Sep 30, 2025 | 2.43 Mn |
| Jun 30, 2025 | 13.34 Mn |
| Jun 30, 2025 | 13.34 Mn |
| Mar 31, 2025 | 12.98 Mn |
| Mar 31, 2025 | 12.98 Mn |
| Dec 31, 2024 | 21.12 Mn |
| Dec 31, 2024 | 21.12 Mn |
| Sep 30, 2024 | 36.75 Mn |
| Sep 30, 2024 | 36.75 Mn |
| Jun 30, 2024 | 32.28 Mn |
| Jun 30, 2024 | 32.28 Mn |
| Mar 31, 2024 | 30.27 Mn |
| Mar 31, 2024 | 30.27 Mn |